var data={"title":"Ciprofloxacin (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ciprofloxacin (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/231814?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ciprofloxacin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ciprofloxacin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=ciprofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ciprofloxacin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611220\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious adverse reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including: tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones in patients who experience any of these serious adverse reactions. Because fluoroquinolones have been associated with serious adverse reactions, reserve ciprofloxacin for use in patients who have no alternative treatment options for the following indications: acute exacerbation of chronic bronchitis, acute sinusitis, and acute uncomplicated cystitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Exacerbation of myasthenia gravis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. Avoid ciprofloxacin in patients with known history of myasthenia gravis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611233\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cipro;</li>\n      <li>Cipro in D5W;</li>\n      <li>Cipro XR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611234\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cipro;</li>\n      <li>Cipro XL;</li>\n      <li>Ciprofloxacin Injection;</li>\n      <li>Ciprofloxacin Injection USP;</li>\n      <li>Ciprofloxacin Intravenous Infusion</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586604\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Quinolone</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442266\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> In pediatric patients, ciprofloxacin is not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for some situations (Bradley 2011b). <b>Note: </b>Oral liquid products are available in two concentrations (ie, 50 mg/mL and 100 mg/mL); precautions should be taken to verify product selection and avoid confusion between the different concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutaneous, without systemic involvement:</i> AAP recommendations (Bradley 2014): Duration: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related event</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preterm neonates (32 to 37 weeks): Oral, immediate release: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Term neonates: Oral, immediate release: 15 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalational (postexposure prophylaxis):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: 15 mg/kg/dose every 12 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AAP recommendation (Bradley 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Preterm neonates (32 to 37 weeks): 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Term infants (&gt;37 weeks): 15 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 mg/kg/dose every 12 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Systemic (including meningitis):</i> AAP recommendations (Bradley 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial treatment as part of combination therapy: Continue until clinical criteria for stability are met.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preterm neonates (32 to 37 weeks): IV: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Term neonates (&gt;37 weeks): IV: 15 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral step-down to complete a 60 day total course:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Preterm neonates (32 to 37 weeks): Oral, immediate release: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Term neonates (&gt;37 weeks): Oral, immediate release: 15 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Plague:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, immediate release: 15 mg/kg/dose every 8 to 12 hours for 10 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 10 mg/kg/dose every 8 to 12 hours for 10 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe infection (eg, sepsis); usually multidrug resistant:</b> Limited data available: IV: 10 mg/kg/dose every 12 hours (Kaguelidou 2011). A study of 20 neonates (28 to 36 weeks) showed this dose produced serum concentrations sufficient to treat common gram-negative pathogens. A higher daily dose divided into shorter intervals may be required to achieve serum concentrations sufficient to treat <i>Staphylococcus aurous</i> or <i>Pseudomonas aeruginosa</i> (Aggarwal 2004). Reported range: 10 to 60 mg/kg/day (Krcm&eacute;ry 1999; Schaad 1995; van den Oever 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586944\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ciprofloxacin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ciprofloxacin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In pediatric patients, ciprofloxacin is not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for some situations [eg, anthrax, resistance (cystic fibrosis)] or in situations where the only alternative is parenteral therapy and ciprofloxacin offers an oral therapy option (Bradley 2011b). <b>Note: </b>Oral liquid products are available in two concentrations (ie, 50 mg/mL and 100 mg/mL); precautions should be taken to verify product selection and avoid confusion between the different concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Extended release tablets and immediate release formulations are not interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate infections: Oral, immediate release: 10 mg/kg/dose twice daily; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe infections:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, immediate release: 15 to 20 mg/kg/dose twice daily; maximum dose: 750 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 10 mg/kg/dose every 8 to 12 hours; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cutaneous, without systemic involvement:</i> AAP recommendations: Oral, immediate release: 15 mg/kg/dose every 12 hours; maximum dose: 500 mg/dose. Duration: 7 to 10 days for naturally acquired infection, up to 60 days for biological weapon-related event (AAP [Bradley 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Inhalational (postexposure prophylaxis): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, immediate release: 15 mg/kg/dose every 12 hours for 60 days; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 10 mg/kg/dose every 12 hours for 60 days; maximum dose: 400 mg/dose; may substitute oral antibiotics for IV antibiotics as soon as clinical condition improves</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Systemic (including meningitis):</i> AAP recommendations (Bradley 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial treatment as part of combination therapy: IV: 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose; continue until clinical criteria for stability are met</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral step-down to complete a 60 day total course: Oral, immediate release: 15 mg/kg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Campylobacteriosis, HIV-exposed/-infected</b> (HHS [adult] 2015): Duration of therapy: 7 to 10 days for gastroenteritis, at least 14 days for bacteremia, 2 to 6 weeks for recurrent bacteremic disease</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: Adolescents: 500 to 750 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Adolescents: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Infant, Children, and Adolescents: Oral, immediate release: 10 to 15 mg/kg/dose once daily; maximum dose: 500 mg/dose (Warady [ISPD 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chancroid:</b> Adolescents: Oral, immediate release: 500 mg twice daily for 3 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 20 mg/kg/dose every 12 hours; maximum dose: 1,000 mg/dose (Stockmann 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose (Stockmann 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, culture negative, empiric therapy:</b> AHA guidelines (Baltimore 2015): Administer in combination with other antibiotics: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 10 to 15 mg/kg/dose twice daily for 4 to 6 weeks; maximum dose: 750 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 10 to 15 mg/kg/dose twice daily for 4 to 6 weeks; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infectious diarrhea:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cholera:</i> Infants, Children, and Adolescents: Oral, immediate release: 15 mg/kg/dose twice daily for 3 days; maximum dose: 500 mg/dose (<i>Red Book</i> [AAP 2015]; WHO 2012). Alternately, 20 mg/kg/dose as a single dose has been used (<i>Red Book</i> [AAP 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Shigellosis dysentery:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-infected: Infants, Children, and Adolescents: Oral, immediate release: 15 mg/kg/dose twice daily for 3 days; maximum dose: 500 mg/dose (WHO 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed-infected (HHS [adult] 2015): Adolescents: Duration of therapy: 7 to 10 days for gastroenteritis, at least 14 days for bacteremia, up to 6 weeks for recurrent infection</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral, immediate release: Adolescents: 500 to 750 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: Adolescents: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> Infants, Children, and Adolescents: IV: 10 to 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose (IDSA [Solomkin 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningococcal invasive disease prophylaxis, high-risk contacts:</b> Infants, Children, and Adolescents: Oral: Immediate release: 20 mg/kg as a single dose, maximum dose 500 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Mycobacterium avium Complex</i>, severe or disseminated disease, HIV-exposed/-infected</b> (HHS [pediatric] 2013): Infants and Children: Oral, immediate release: 10 to 15 mg/kg/dose twice daily in addition to other antibiotics; maximum dose: 750 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plague</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, immediate release: 15 mg/kg/dose every 8 to 12 hours for 10 to 21 days; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 10 mg/kg/dose every 8 to 12 hours for 10 to 21 days; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (CDC [plague] 2015): Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial treatment: IV: 15 mg/kg/dose every 12 hours; maximum dose: 400 mg/dose; continue until 2 days after fever subsides, then may change to oral therapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral step-down to complete a 10 to 14 day course: Oral, immediate release: 20 mg/kg/dose twice daily; maximum dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Postexposure prophylaxis: Oral, immediate release: 20 mg/kg twice daily for 7 days; maximum dose: 500 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community acquired <i>(Haemophilus influenza)</i></b>: Infants &gt;3 months and Children: IV: 15 mg/kg/dose every 12 hours (IDSA/PIDS [Bradley 2011a])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Salmonellosis, HIV-exposed/-infected</b> (HHS [adult] 2015): Duration of therapy: At least 7 to 14 days if CD4 &gt; 200 cells/mm<sup>2</sup>, 2 to 6 weeks if CD4 &lt;200 cells/mm<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: Adolescents: 500 to 750 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Adolescents: 400 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 10 mg/kg within 120 minutes prior to surgical incision; maximum dose: 400 mg/dose (ASHP [Bratzler 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tularemia, mild disease:</b> Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment or contained casualty situation:</i> IV: 15 mg/kg/dose twice daily for at least 10 days; maximum dose: 400 mg/dose (Dennis 2001; WHO 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis, mass casualty situation:</i> Oral, immediate release: 15 mg/kg/dose twice daily for 14 days; maximum dose: 500 mg/dose (Dennis 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cystitis, acute uncomplicated:</i> Adolescents &ge; 18 years: Oral, extended release: 500 mg every 24 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Complicated (including pyelonephritis): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, immediate release: Children and Adolescents: 10 to 20 mg/kg/dose every 12 hours for 10 to 21 days; maximum dose: 750 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, extended release: Adolescents &ge;18 years: 1,000 mg every 24 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Children and Adolescents: 6 to 10 mg/kg/dose every 8 hours for 10 to 21 days; maximum dose: 400 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anthrax: Inhalational (postexposure prophylaxis):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 mg every 12 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 12 hours for 60 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone/joint infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 to 750 mg twice daily for 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild/moderate: 400 mg every 12 hours for 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe/complicated: 400 mg every 8 hours for 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystitis, acute uncomplicated:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 250 mg every 12 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, extended release: 500 mg every 24 hours for 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia:</b> IV: 400 mg every 8 hours for 7 to 14 days (in combination therapy with piperacillin)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Granuloma inguinale (donovanosis):</b> Oral, immediate release: 750 mg twice daily for at least 3 weeks or until all lesions have completely healed (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Infectious diarrhea:</b> Oral, immediate release: 500 mg every 12 hours for 5 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal, complicated (in combination with metronidazole): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 12 hours for 7 to 14 days; <b>Note:</b> IDSA guidelines recommend treatment duration of 4 to 7 days (provided source controlled) (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lower respiratory tract infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 to 750 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 8 to 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nosocomial pneumonia:</b> IV: 400 mg every 8 hours for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plague:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 to 750 mg every 12 hours for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 8 to 12 hours for 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prostatitis (chronic, bacterial):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 mg every 12 hours for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 12 hours for 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sinusitis (acute): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 400 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin/skin structure infections:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 500 to 750 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Mild to moderate: 400 mg every 12 hours for 7 to 14 days; Severe/complicated: 400 mg every 8 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Typhoid fever:</b> Oral, immediate release: 500 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, immediate release: 250 to 500 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 200 to 400 mg every 8 to 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infection, complicated (including uncomplicated pyelonephritis):</b> Oral, extended release: 1,000 mg every 24 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV and Oral, immediate release: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR 10 to 29 mL/minute/1.73m<sup>2</sup>: 10 to 15 mg/kg/dose every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">GFR &lt;10 mL/minute/1.73m<sup>2</sup>: 10 to 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis/peritoneal dialysis (PD) (after dialysis on dialysis days): Minimally dialyzable (&lt;10%): 10 to 15 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CRRT: 10 to 15 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, extended release: Adolescents &ge;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, immediate release:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 30 to 50 mL/minute: Oral: 250 to 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 5 to 29 mL/minute: 250 to 500 mg every 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 250 to 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral, extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;30 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis/peritoneal dialysis (PD) (administer after dialysis on dialysis days): 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 5 to 29 mL/minute: 200 to 400 mg every 18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: Oral (immediate release), IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute: Administer 50% to 75% of usual dose every 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer 50% of usual dose every 12 hours (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Minimally dialyzable (&lt;10%): Oral: 250 to 500 mg every 24 hours or IV: 200 to 400 mg every 24 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CVVH/CVVHD/CVVHDF: IV: 200 to 400 mg every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; use with caution in severe impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611523\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro in D5W: 200 mg/100 mL (100 mL [DSC]) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/100 mL (100 mL); 400 mg/200 mL (200 mL); 200 mg/20 mL (20 mL [DSC]); 400 mg/40 mL (40 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro in D5W: 200 mg/100 mL (100 mL [DSC]); 400 mg/200 mL (200 mL) [latex free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/100 mL (100 mL); 400 mg/200 mL (200 mL); 200 mg/20 mL (20 mL); 400 mg/40 mL (40 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro: 250 mg/5 mL (100 mL); 500 mg/5 mL (100 mL) [strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/5 mL (100 mL [DSC]); 500 mg/5 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 250 mg, 500 mg, 750 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as base and hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro XR: 500 mg, 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 1000 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611236\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611231\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cipro: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019537s087,020780s044lbl.pdf#page=41&amp;token=afrhIpcbZFX4oRFb2twpYUzxqF82YuMQVo5cVtn7YrDqZQhBQb6uvO53Nku5Gl+Xb8t6znCszLEWEK1lyMFX3ZfqlggGrjol4AhU6CJafm8jgn0rwd3G58A6UDEewfdY&amp;TOPIC_ID=15951\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019537s087,020780s044lbl.pdf#page=41</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586949\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: May administer with food to minimize GI upset; divalent and trivalent cations [dairy foods (milk, yogurt) and mineral supplements (eg, iron, zinc, calcium) or calcium-fortified juices] decrease ciprofloxacin absorption; usual dietary calcium intake (including meals which include dairy products) has not been shown to interfere with ciprofloxacin absorption (per manufacturer). Administer immediate release ciprofloxacin and Cipro XR at least 2 hours before or 6 hours after any of these products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension: Shake vigorously prior to each dose. Should not be administered through feeding tubes (suspension is oil-based and adheres to the feeding tube). Patients should avoid chewing on the microcapsules. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Administering 2 hours after meals is preferable.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Do not crush, split, or chew. May be administered with meals containing dairy products (calcium content &lt;800 mg), but not with dairy products alone. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasogastric/orogastric tube: Crush immediate release tablet and mix with water. Flush feeding tube before and after administration. Hold tube feedings at least 1 hour before and 2 hours after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Administer by slow IV infusion over 60 minutes to reduce the risk of venous irritation (burning, pain, erythema, and swelling)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611353\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premixed infusion: Store between 5&deg;C to 25&deg;C (41&deg;F to 77&deg;F); avoid freezing. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vial: Store between 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F); avoid freezing. Protect from light. Diluted solutions of 0.5 to 2 mg/mL in D5<sup>1</sup>/<sub>4</sub>NS, D5<sup>1</sup>/<sub>2</sub>NS, D5W, D10W, LR, NS are stable for up to 14 days refrigerated or at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Microcapsules for oral suspension: Prior to reconstitution, store below 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from freezing. Following reconstitution, store at 25&deg;C (77&deg;F) for 14 days; excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) for up to 14 days. Protect from freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586605\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Intravenous and immediate release oral formulations: Treatment and prophylaxis of plague and postexposure prophylaxis of inhalational anthrax (FDA approved in all ages); treatment of complicated urinary tract infection and pyelonephritis (FDA approved in ages 1 to 17 years); treatment of urinary tract infections, chronic bacterial prostatitis, lower respiratory tract infections, acute exacerbation of chronic bronchitis, skin and skin structure infections, bone and joint infections, and acute sinusitis (FDA approved in adults); treatment of complicated intra-abdominal infections (with metronidazole; FDA approved in adults); treatment of acute uncomplicated cystitis, infectious diarrhea, and typhoid fever (oral formulations only; FDA approved in adults); treatment of nosocomial pneumonia (IV preparation only; FDA approved in adults); treatment of febrile neutropenia (with piperacillin; IV preparation only; FDA approved in adults); has also been used for prophylaxis of surgical site infection and invasive meningococcal disease, chancroid, endocarditis, granuloma inguinale, tularemia, and infections in HIV-exposed/-infected patients (campylobacter, <i>Isospora belli</i>, MAC, salmonella)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release tablet: Treatment of urinary tract infections and acute uncomplicated pyelonephritis (FDA approved in ages &ge;18 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Although FDA approved in adults for treatment of uncomplicated cervical and urethral gonorrhea, the CDC no longer recommends the use of fluoroquinolones for the treatment of gonococcal disease (CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3198418\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ciprofloxacin may be confused with cephalexin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cipro may be confused with Ceftin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611306\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (IV administration), neurological signs and symptoms (children; includes dizziness, insomnia, nervousness, somnolence), restlessness (IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain (more common in children), diarrhea (more common in children), dyspepsia (more common in children), nausea, vomiting (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT, increased serum AST (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (IV administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Rhinitis (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (more common in children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abnormal gait, acute generalized exanthematous pustulosis, acute gout attack, acute renal failure, ageusia, agitation, agranulocytosis, albuminuria, anaphylactic shock, anaphylaxis, anemia, angina pectoris, angioedema, anorexia, anosmia, anxiety, arthralgia, ataxia, atrial flutter, bone marrow depression (life-threatening), bronchospasm, candidiasis, candiduria, cardiorespiratory arrest, casts in urine, cerebral thrombosis, chills, cholestatic jaundice, chromatopsia, <i>Clostridium difficile</i>-associated diarrhea, confusion, constipation, crystalluria (particularly in alkaline urine), decreased hematocrit, decreased hemoglobin, decreased prothrombin time, delirium, depersonalization, depression (including self-injurious behavior), dizziness, drowsiness, dyspepsia (adults), dysphagia, dysphasia, dyspnea, edema, eosinophilia, erythema multiforme, erythema nodosum, exacerbation of myasthenia gravis, exfoliative dermatitis, fixed drug eruption, flatulence, gastrointestinal hemorrhage, hallucination, headache (oral), hematuria, hemolytic anemia, hepatic failure, hepatic necrosis, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hyperesthesia, hyperglycemia, hyperpigmentation, hypersensitivity reaction, hypertension, hypertonia, hypoglycemia, hypotension, increased blood urea nitrogen, increased creatine phosphokinase, increased INR (in patients treated with vitamin K antagonists), increased intracranial pressure, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum bilirubin, increased serum cholesterol, increased serum creatinine, increased serum glucose, increased serum lipase, increased serum triglycerides, increased uric acid, insomnia, interstitial nephritis, intestinal perforation, irritability, jaundice, laryngeal edema, lethargy, lymphadenopathy, malaise, manic behavior, mastalgia, methemoglobinemia, migraine, myalgia, myocardial infarction, myoclonus, nephritis, nephrolithiasis, nightmares, nystagmus, orthostatic hypotension, palpitations, pancreatitis, pancytopenia (life-threatening), paranoia, paresthesia, peripheral neuropathy, petechia, phobia, phototoxicity, pneumonitis, polyneuropathy, prolonged prothrombin time (in patients treated with vitamin K antagonists), pseudotumor cerebri, pulmonary edema, rupture of tendon, seizure (including grand mal), serum sickness-like reaction, skin photosensitivity, status epilepticus, Stevens-Johnson syndrome, suicidal ideation, suicidal tendencies, syncope, tachycardia, tendonitis, thrombocythemia, thrombocytopenia, thrombophlebitis, tinnitus, torsades de pointes, toxic epidermal necrolysis, toxic psychosis, tremor, twitching, unresponsive to stimuli, urethral bleeding, vaginitis, vasculitis, ventricular arrhythmia, ventricular ectopy, visual disturbance, vulvovaginal candidiasis, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611301\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones; concurrent administration of tizanidine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Concurrent administration of agomelatine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611302\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Altered cardiac conduction: Fluoroquinolones may prolong QT<sub>c</sub> interval; avoid use in patients with a history of or at risk for QT<sub>c</sub> prolongation, torsade de pointes, uncorrected hypokalemia, hypomagnesemia, cardiac disease (heart failure, myocardial infarction, bradycardia) or concurrent administration of other medications known to prolong the QT interval (including Class Ia and Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, and tricyclic antidepressants).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Crystalluria: Rarely, crystalluria has occurred; urine alkalinity may increase the risk. Ensure adequate hydration during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose regulation: Fluoroquinolones have been associated with the development of serious, and sometimes fatal, hypoglycemia. These events have occurred most often in elderly patients with diabetes, but have also been reported in patients without a prior history of diabetes. Prompt identification and treatment of hypoglycemia is essential. Individual quinolones may differ in their potential to cause this effect. It was most evident with gatifloxacin (no longer marketed as a systemic formulation). Hyperglycemia has also been associated with the use of fluoroquinolones. Patients should be monitored closely for signs/symptoms of disordered glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity:  Hepatocellular, cholestatic, or mixed liver injury has been reported, including hepatic necrosis, life-threatening hepatic events, and fatalities. Acute liver injury can be rapid onset (range: 1-39 days), often associated with hypersensitivity. Most fatalities occurred in patients &gt;55 years of age. Discontinue immediately if signs/symptoms of hepatitis (abdominal tenderness, dark urine, jaundice, pruritus) occur. Additionally, temporary increases in transaminases or alkaline phosphatase, or cholestatic jaundice may occur (highest risk in patients with previous liver damage).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, have occurred with quinolone therapy. The spectrum of these reactions can vary widely; reactions may present as typical allergic symptoms (eg, itching, urticaria, rash, edema) after a single dose, or may manifest as severe idiosyncratic dermatologic (eg, Stevens-Johnson, toxic epidermal necrolysis), vascular (eg, vasculitis), pulmonary (eg, pneumonitis), renal (eg, nephritis), hepatic (eg, hepatitis, jaundice, hepatic failure or necrosis), and/or hematologic (eg, anemia, cytopenias) events, usually after multiple doses. Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity/phototoxicity: Avoid excessive sunlight and take precautions to limit exposure (eg, loose fitting clothing, sunscreen); may cause moderate-to-severe phototoxicity reactions which may appear as exaggerated sunburn reactions. Discontinue use if phototoxicity occurs. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Serious adverse reactions:<b>[US Boxed Warning]: Fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ciprofloxacin immediately and avoid use of fluoroquinolones in patients who experience any of these serious adverse reactions.</b> Patients of any age or without preexisting risk factors have experienced these reactions; may occur within hours to weeks after initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- CNS effects: Fluoroquinolones have been associated with an increased risk of CNS effects including seizures, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis; may also cause nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or actions. May occur following the first dose; discontinue immediately and avoid further use of fluoroquinolones in patients who experience these reactions. Use with caution in patients with known or suspected CNS disorder, or risk factors that may predispose to seizures or lower the seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Peripheral neuropathy: Fluoroquinolones have been associated with an increased risk of peripheral neuropathy; may occur soon after initiation of therapy and may be irreversible; discontinue if symptoms of sensory or sensorimotor neuropathy occur. Avoid use in patients who have previously experienced peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">- Tendinitis/tendon rupture: Fluoroquinolones have been associated with an increased risk of tendonitis and tendon rupture in all ages; risk may be increased with concurrent corticosteroids, solid organ transplant recipients, and in patients &gt;60 years of age, but has also occurred in patients without these risk factors. Rupture of the Achilles tendon has been reported most frequently; but other tendon sites (eg, rotator cuff, biceps, hand) have also been reported. Inflammation and rupture may occur bilaterally. Cases have been reported within hours or days of initiation, and up to several months after discontinuation of therapy. Strenuous physical activity, renal failure, and previous tendon disorders may be independent risk factor for tendon rupture. Discontinue at first sign of tendon pain, swelling, inflammation or rupture. Avoid use in patients with a history of tendon disorders or who have experienced tendinitis or tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: <b>[US Boxed Warning]: May exacerbate muscle weakness related to myasthenia gravis; avoid use in patients with a known history of myasthenia gravis.</b> Cases of severe exacerbations, including the need for ventilatory support and deaths have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required. May increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may increase risk of tendon rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Syphilis: Since ciprofloxacin is ineffective in the treatment of syphilis and may mask symptoms, all patients should be tested for syphilis at the time of gonorrheal diagnosis and 3 months later.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Theophylline: Serious and fatal reactions including seizures, status epilepticus, cardiac arrest, and respiratory failure have been reported with concomitant administration of theophylline. If concurrent use is unavoidable, monitor serum theophylline levels and adjust theophylline dose as warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Adverse effects (eg, tendon rupture, QT changes) may be increased in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Hemolytic reactions may (rarely) occur with quinolone use in patients with latent or actual G6PD deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric:  Adverse effects, including those related to joints and/or surrounding tissues, are increased in pediatric patients and therefore, ciprofloxacin should not be considered as drug of choice in children (exception is anthrax treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: <b>[US Boxed Warning]: Reserve use of ciprofloxacin for treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, or acute uncomplicated cystitis for patients who have no alternative treatment options because of the risk of disabling and potentially serious adverse reactions (eg, tendinitis and tendon rupture, peripheral neuropathy, CNS effects).</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25855423\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Increased osteochondrosis in immature rats and dogs was observed with ciprofloxacin and fluoroquinolones have caused arthropathy with erosions of the cartilage in weight-bearing joints of immature animals. In an international safety data analysis of ciprofloxacin in approximately 700 pediatric patients (1 to 17 years), the follow-up arthropathy rate at 6 weeks and cumulative arthropathy rate at 1 year were higher in ciprofloxacin treatment group than comparative controls (6 weeks: 9.3% vs 6%; 1 year: 13.7% to 9.5%). In pediatric patients, fluoroquinolones are not routinely first-line therapy, but after assessment of risks and benefits, can be considered a reasonable alternative for situations where no safe and effective substitute is available (eg, resistance [anthrax, common CF pathogens, multidrug resistant tuberculosis]) or in situations where the only alternative is parenteral therapy and ciprofloxacin offers an oral therapy option (Bradley 2011b). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611328\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3, P-glycoprotein/ABCB1; <b>Inhibits</b> CYP1A2 (moderate), CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611329\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15951&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agomelatine: Ciprofloxacin (Systemic) may increase the serum concentration of Agomelatine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alosetron: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Quinolones. Of concern only with oral administration of quinolones. Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May increase the serum concentration of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bendamustine: Ciprofloxacin (Systemic) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Quinolones may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine: Ciprofloxacin (Systemic) may increase the serum concentration of Caffeine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Quinolones. Of concern only with oral administration of both agents.<b> Exceptions: </b>Calcium Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Ciprofloxacin (Systemic) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Ciprofloxacin (Systemic) may enhance the QTc-prolonging effect of CloZAPine. Ciprofloxacin (Systemic) may increase the serum concentration of CloZAPine.  Management: Reduce the clozapine dose to one-third of the original dose when adding ciprofloxacin and monitor closely for evidence of excessive QTc prolongation and clozapine toxicity.  Resume the previous clozapine dose following ciprofloxacin discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inhibitors): CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: Quinolones may enhance the QTc-prolonging effect of Delamanid.  Management: Avoid concomitant use of delamanid and quinolone antibiotics if possible. If coadministration is considered to be unavoidable, frequent monitoring of electrocardiograms (ECGs) throughout the full delamanid treatment period should occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Quinolones may decrease the serum concentration of Didanosine. Didanosine may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones at least 2 hours before or 6 hours after didanosine. Monitor for decreased therapeutic effects of quinolones, particularly if doses cannot be separated as recommended. This does not apply to unbuffered enteric coated didanosine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Ciprofloxacin (Systemic) may increase the serum concentration of Erlotinib.  Management: Avoid use of this combination when possible.  When the combination must be used, monitor the patient closely for the development of severe adverse reactions, and if such severe reactions occur, reduce the erlotinib dose (in 50 mg decrements).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May enhance the QTc-prolonging effect of Ciprofloxacin (Systemic). Ciprofloxacin (Systemic) may diminish the therapeutic effect of Fosphenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Quinolones may enhance the adverse/toxic effect of Heroin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: Ciprofloxacin (Systemic) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kola Nut: Ciprofloxacin (Systemic) may increase the serum concentration of Kola Nut. Specifically, ciprofloxacin may increase serum concentrations of caffeine, a major component of kola nut. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Quinolones. Management: Administer oral quinolone antibiotics at least one hour before or four hours after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: Ciprofloxacin (Systemic) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meptazinol: May decrease the serum concentration of Ciprofloxacin (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Ciprofloxacin (Systemic) may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Quinolones. Specifically, polyvalent cations in multivitamin products may decrease the absorption of orally administered quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. Management: Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Quinolones may decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nadifloxacin: May enhance the adverse/toxic effect of Quinolones.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Ciprofloxacin (Systemic) may increase the serum concentration of Neratinib.  Management: Avoid concomitant use of neratinib and ciprofloxacin if possible. If combined, monitor for increased neratinib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: Ciprofloxacin (Systemic) may increase the serum concentration of Olaparib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patiromer: May decrease the serum concentration of Ciprofloxacin (Systemic). Management: Administer oral ciprofloxacin at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: Ciprofloxacin (Systemic) may increase the serum concentration of Pentoxifylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Ciprofloxacin (Systemic) may diminish the therapeutic effect of Phenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pirfenidone: Ciprofloxacin (Systemic) may increase the serum concentration of Pirfenidone.  Management: With ciprofloxacin doses of 1,500 mg/day, the pirfenidone dose should be reduced to 1,602 mg daily (ie, 534 mg three times a day). With lower daily doses of ciprofloxacin, use pirfenidone with caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Ciprofloxacin (Systemic) may increase the serum concentration of Pomalidomide.  Management: Avoid concomitant use of pomalidomide and ciprofloxacin when possible. If coadministration is considered necessary, consider reducing the pomalidomide dose 50% and monitoring patients for increased pomalidomide effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Quinolones. Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rasagiline: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: Ciprofloxacin (Systemic) may increase the serum concentration of Roflumilast. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: Ciprofloxacin (Systemic) may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ropivacaine: Ciprofloxacin (Systemic) may increase the serum concentration of Ropivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the absorption of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after sevelamer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the arrhythmogenic effect of Ciprofloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Quinolones. Management: In order to minimize any potential impact of strontium ranelate on quinolone antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during quinolone therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Quinolones. Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Quinolones may decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents. <b> Exceptions: </b>Dyphylline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Ciprofloxacin (Systemic) may decrease the serum concentration of Thyroid Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: Ciprofloxacin (Systemic) may increase the serum concentration of TiZANidine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Quinolones may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concurrent use of levofloxacin or other quinolone antibiotics, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Quinolones may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the serum concentration of Quinolones. Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, pe- or ofloxacin or nalidixic acid) oral zinc salts.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: Ciprofloxacin (Systemic) may increase the serum concentration of Zolpidem.  Management: Consider avoiding the combination of ciprofloxacin and zolpidem if possible. If combined, monitor for signs of zolpidem toxicity (eg, somnolence, dizziness, lethargy).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611333\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases rate, but not extent, of absorption. Ciprofloxacin may increase serum caffeine levels if taken concurrently. Rarely, crystalluria may occur. Enteral feedings may decrease plasma concentrations of ciprofloxacin probably by &gt;30% inhibition of absorption. Management: May administer with most foods to minimize GI upset. If unable to avoid the following foods, administer ciprofloxacin at least 2 hours before or 6 hours after dairy products or calcium-fortified juices alone or in a meal containing &gt;800 mg calcium. Restrict caffeine intake if excessive cardiac or CNS stimulation occurs. Ensure adequate hydration during therapy. Ciprofloxacin should not be administered with enteral feedings. The feeding would need to be discontinued for 1 to 2 hours prior to and after ciprofloxacin administration. Nasogastric administration produces a greater loss of ciprofloxacin bioavailability than does nasoduodenal administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611259\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611260\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Ciprofloxacin crosses the placenta and produces measurable concentrations in the amniotic fluid and cord serum (Ludlam 1997). Based on available data, an increased risk of teratogenic effects has not been observed following ciprofloxacin use during pregnancy (Bar-Oz 2009; Padberg 2014). Ciprofloxacin is recommended for prophylaxis and treatment of pregnant women exposed to anthrax (Meaney-Delman 2014). Serum concentrations of ciprofloxacin may be lower during pregnancy than in nonpregnant patients (Giamarellou 1989). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10587004\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor renal, hepatic, and hematopoietic function periodically; monitor number and type of stools/day for diarrhea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10587005\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic: 2.6 to 3 mcg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611370\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611373\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well-absorbed; 500 mg orally every 12 hours produces an equivalent AUC to that produced by 400 mg IV over 60 minutes every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 2.1 to 2.7 L/kg; tissue concentrations often exceed serum concentrations especially in kidneys, gallbladder, liver, lungs, gynecological tissue, and prostatic tissue; CSF concentrations: 10% of serum concentrations (noninflamed meninges), 14% to 37% (inflamed meninges)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 20% to 40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Partially hepatic; forms 4 metabolites (limited activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 50% to 85%; younger CF patients have a lower bioavailability of 68% vs CF patients &gt;13 years of age with bioavailability of 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children: 4 to 5 hours; Adults: Normal renal function: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Immediate release tablet: 0.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Extended release tablet: Cipro XR: 1 to 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (30% to 50% as unchanged drug); feces (15% to 43%; &lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Clearance: After IV: CF children: 0.84 L/hour/kg; Adults: 0.5 to 0.6 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10806353\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 50 mg/mL oral suspension may be made using 2 different vehicles (a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Methylcellulose 1% and Simple Syrup, NF). Crush twenty 500 mg tablets and reduce to a fine powder. Add a small amount of vehicle and mix to a uniform paste; mix while adding the vehicle in geometric proportions to <b>almost</b> 200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable 91 days refrigerated and 70 days at room temperature. <b>Note:</b> Microcapsules for oral suspension available (50 mg/mL; 100 mg/mL); not for use in feeding tubes.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611525\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cipro in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL (200 mL): $30.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ciprofloxacin in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $2.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/200 mL (200 mL): $3.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ciprofloxacin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/20 mL (20 mL): $2.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg/40 mL (40 mL): $4.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cipro Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 MG/5ML (5%) (100 mL): $149.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 MG/5ML (10%) (100 mL): $174.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Ciprofloxacin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 MG/5ML (10%) (100 mL): $142.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Cipro XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $523.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (50): $595.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Ciprofloxacin-Ciproflox HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $489.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (50): $557.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cipro Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $588.11</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $688.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ciprofloxacin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (6): $91.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $443.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $530.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 mg (50): $277.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961927\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AC Ear Drops (IN);</li>\n      <li>Acipro (PH);</li>\n      <li>Aciren (KR);</li>\n      <li>Adiflox (IN);</li>\n      <li>Alcon Cilox (CO, ID);</li>\n      <li>Antox (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Apoflox (MX);</li>\n      <li>Aprocin (HK);</li>\n      <li>Asflox (ET);</li>\n      <li>Bacquinor (ID);</li>\n      <li>Bactiflox (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Baflox (CO);</li>\n      <li>Baquinor (ID);</li>\n      <li>Baycip (CL, ES);</li>\n      <li>Bearcin (KR);</li>\n      <li>Bernoflox (ID);</li>\n      <li>C-Flox (AU, UY);</li>\n      <li>Cefaxin (KR);</li>\n      <li>Ceflox (IN);</li>\n      <li>Cetraxal (CR, DO, ES, GT, HN, NI, PA, SV);</li>\n      <li>Ciclodin (PH);</li>\n      <li>Cifex (PH);</li>\n      <li>Cifloc (ZA);</li>\n      <li>Ciflodal (PH);</li>\n      <li>Cifloptic (PE);</li>\n      <li>Ciflox (AE, FR, HR, KW, QA, VE);</li>\n      <li>Cifloxager (IE);</li>\n      <li>Cifloxin (HK, PH);</li>\n      <li>Cifox (IE);</li>\n      <li>Cifran (AU, BF, BJ, CI, CN, ET, GH, GM, GN, IN, KE, LK, LR, LV, MA, ML, MR, MU, MW, NE, NG, RO, SC, SD, SL, SN, TN, TZ, UG, VN, ZM, ZW);</li>\n      <li>Cilobact (CO);</li>\n      <li>Cilox (NO);</li>\n      <li>Cimoxin (PE);</li>\n      <li>Cinaflox (PE);</li>\n      <li>Cipflox (NZ);</li>\n      <li>Ciploc (PK);</li>\n      <li>Ciplox (BF, BJ, CI, ET, GH, GM, GN, HK, IE, KE, LR, LV, MA, ML, MR, MU, MW, NE, NG, SC, SD, SK, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Ciplus (KR);</li>\n      <li>Ciprecu (EC);</li>\n      <li>Ciprinol (BG, EE, LV, RO, SI);</li>\n      <li>Cipro (AR, BR, CO, JO, PY);</li>\n      <li>Cipro A (BD);</li>\n      <li>Cipro XR (BB, BM);</li>\n      <li>Cipro-Denk (TZ);</li>\n      <li>Ciprobac (MX);</li>\n      <li>Ciprobay (AE, BG, BH, CY, CZ, EG, IQ, IR, JO, KR, KW, LB, LY, MY, OM, PH, PL, QA, SA, SI, SY, TH, VN, YE, ZA, ZW);</li>\n      <li>Ciprobay Uro (DE);</li>\n      <li>Ciprobeta (DE);</li>\n      <li>Ciprobid (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TH, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Ciprobiotic (GT, HN, ID, NI);</li>\n      <li>Ciprocan (KR);</li>\n      <li>Ciprocep (TH);</li>\n      <li>Ciprocin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ciprodac (ZW);</li>\n      <li>Ciprodar (AE, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ciprodex (IL);</li>\n      <li>Ciproflox (CY, PE, SA);</li>\n      <li>Ciprogis (IL);</li>\n      <li>Ciproglen (MY);</li>\n      <li>Ciprol (AU);</li>\n      <li>Ciprolak (PE);</li>\n      <li>Ciprolet (SG);</li>\n      <li>Ciprolin (PE);</li>\n      <li>Ciprolon (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cipromed (PE);</li>\n      <li>Cipromycin (GR);</li>\n      <li>Cipropharm (AE, BH, CY, EG, ET, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ciprophil (PH);</li>\n      <li>Ciprotal (PH);</li>\n      <li>Ciprouro SR (KR);</li>\n      <li>Ciproval (CL);</li>\n      <li>Ciprovar (ZW);</li>\n      <li>Ciprox (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SY, YE);</li>\n      <li>Ciproxan (JP);</li>\n      <li>Ciproxin (AT, AU, CH, DK, FI, GB, GR, HK, ID, IE, IT, KR, MT, NO, NZ, SE, TR, TW, ZW);</li>\n      <li>Ciproxina (BB, BM, BS, BZ, CR, CU, DO, EC, GT, HN, JM, MX, NI, NL, PA, PR, PT, SR, SV, TT);</li>\n      <li>Ciproxine (BE, LU);</li>\n      <li>Ciproxyl (HK, TH);</li>\n      <li>Cipzy (LK);</li>\n      <li>Ciriax (PE);</li>\n      <li>Cirok (PH, SG);</li>\n      <li>Ciroxin (TW);</li>\n      <li>Cirpobay (CN);</li>\n      <li>Citopcin (KR);</li>\n      <li>Cixa (TW);</li>\n      <li>Cobay (TH);</li>\n      <li>Cobay-500 (PH);</li>\n      <li>Cosflox (IN);</li>\n      <li>Cycin (KR, SG);</li>\n      <li>Cyplox (HK);</li>\n      <li>Cypral (VE);</li>\n      <li>Cypro (KR);</li>\n      <li>Dibactil (PY);</li>\n      <li>Eni (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Enoxin (SG, TH);</li>\n      <li>Eprocin (KR);</li>\n      <li>Estecina (ES);</li>\n      <li>Fexin (PH);</li>\n      <li>Flaproks (UA);</li>\n      <li>Floroxin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Floxabid (BD);</li>\n      <li>Floxager (MX);</li>\n      <li>Floxine (ET);</li>\n      <li>Floxsid (ID);</li>\n      <li>Glocip (VN);</li>\n      <li>Glojaya (ID);</li>\n      <li>Hexiquin (ID);</li>\n      <li>Hiflox (BD);</li>\n      <li>Hippro (TH);</li>\n      <li>Hippro Forte (TH);</li>\n      <li>Ifloxin (PH);</li>\n      <li>Interflox (ID);</li>\n      <li>Iprolan (PH);</li>\n      <li>Iprubac (PH);</li>\n      <li>Jayacin (ID);</li>\n      <li>Ladinin (ET);</li>\n      <li>Lofucin (KR);</li>\n      <li>Loxan (CO);</li>\n      <li>Maxpro (PH);</li>\n      <li>Medcoflox (ID);</li>\n      <li>Novaflox (SG);</li>\n      <li>Novidat (AR);</li>\n      <li>Oftacilox (PT);</li>\n      <li>Optal-Pro (TH);</li>\n      <li>Orlin (AE);</li>\n      <li>Orpic (PH);</li>\n      <li>Otosec (CO, PE);</li>\n      <li>Procip (NZ, ZW);</li>\n      <li>Proflox (EC, TH);</li>\n      <li>Profloxin (IE);</li>\n      <li>Proquin (AU);</li>\n      <li>Proxacin (BD, BR);</li>\n      <li>Pycip (MY);</li>\n      <li>Qilaflox (ID);</li>\n      <li>Qinosyn (PH);</li>\n      <li>Quilox (PH);</li>\n      <li>Quinobiotic (ID, PE);</li>\n      <li>Quinocip (LK);</li>\n      <li>Quinos (KR);</li>\n      <li>Quintor (ET);</li>\n      <li>Qupron (KR);</li>\n      <li>Sepcen (MT);</li>\n      <li>Serviflox (MY, SG);</li>\n      <li>Sifloks (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Siflox (ID);</li>\n      <li>Sophixin Ofteno (CR, DO, GT, HN, NI, PA, SV, VE);</li>\n      <li>Superocin (TW);</li>\n      <li>Supraflox (ET);</li>\n      <li>Tequinol (ID);</li>\n      <li>Topistin (SG);</li>\n      <li>Truoxin (IE);</li>\n      <li>Tsyprobay (UA);</li>\n      <li>Tsyprynol (UA);</li>\n      <li>Tyflox (ZW);</li>\n      <li>Unex (EC);</li>\n      <li>Uniflox (FR);</li>\n      <li>Uroxin (HK, SG);</li>\n      <li>Vexcipro (PH);</li>\n      <li>Viflox (ID);</li>\n      <li>Vistaflox (PH);</li>\n      <li>Xenoflox (PH);</li>\n      <li>Zindolin (TR);</li>\n      <li>Zumaflox (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aggarwal P, Dutta S, Garg SK, et al, &quot;Multiple Dose Pharmacokinetics of Ciprofloxacin in Preterm Babies,&quot; <i> Indian Pediatr</i>, 2004, 41(10):1001-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/15523125/pubmed\" target=\"_blank\" id=\"15523125\">15523125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 66, 171.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/26373317 /pubmed\" target=\"_blank\" id=\"26373317 \">26373317 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Moretti ME, Boskovic R, O'Brien L, Koren G. The safety of quinolones--a meta-analysis of pregnancy outcomes. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2009;143(2):75-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/19181435 /pubmed\" target=\"_blank\" id=\"19181435 \">19181435 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011a, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. <i>Pediatrics</i>. 2011b;128:e1034-1045.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/21949152/pubmed\" target=\"_blank\" id=\"21949152\">21949152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):e1411-1436.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/24777226 /pubmed\" target=\"_blank\" id=\"24777226 \">24777226 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/23327981 /pubmed\" target=\"_blank\" id=\"23327981 \">23327981 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campoli-Richards DM, Monk JP, Price A, et al, &quot;Ciprofloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use,&quot; <i>Drugs</i>, 1988, 35(4):373-447.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/3292209/pubmed\" target=\"_blank\" id=\"3292209\">3292209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Plague. Resources for Clinicians. Available at <a href=\"http://www.cdc.gov/plague/healthcare/clinicians.html#treatment\" target=\"_blank\">http://www.cdc.gov/plague/healthcare/clinicians.html#treatment</a>. Updated December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro IV injection (ciprofloxacin systemic) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro tablet (ciprofloxacin systemic) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cipro XR tablet (ciprofloxacin systemic) [prescribing information]. West Haven, CT: Bayer Pharmaceuticals Corporation; August 2003.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. <i>JAMA</i>. 2001;285(21):2763-2773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/11386933 /pubmed\" target=\"_blank\" id=\"11386933 \">11386933 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardner DK, Gabbe SG, and Harter C, &quot;Simultaneous Concentrations of Ciprofloxacin in Breast Milk and in Serum in Mother and Breast-Fed Infant,&quot; <i>Clin Pharm</i>, 1992, 11(4):352-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/1563233/pubmed\" target=\"_blank\" id=\"1563233\">1563233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giamarellou H, Kolokythas E, Petrikkos G, et al, &ldquo;Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women,&rdquo; <i>Am J Med</i>, 1989, 87(Suppl 5A):49-51.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harmon T, Burkhart G, and Applebaum H, &quot;Perforated Pseudomembranous Colitis in the Breast-Fed Infant,&quot; <i>J Pediatr Surg</i>, 1992, 27(6):744-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/1501036/pubmed\" target=\"_blank\" id=\"1501036\">1501036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services (HHS). Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. 2013. Available at <a href=\"http://aidsinfo.nih.gov/guidelines\" target=\"_blank\">http://aidsinfo.nih.gov/guidelines</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/19397464 /pubmed\" target=\"_blank\" id=\"19397464 \">19397464 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inglesby TV, Henderson DA, Bartlett JG, et al, &quot;Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense,&quot; <i>JAMA</i>, 1999, 281(18):1735-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/10328075/pubmed\" target=\"_blank\" id=\"10328075\">10328075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaguelidou F, Turner MA, Choonara I, et al, &quot;Ciprofloxacin Use in Neonates: A Systematic Review of the Literature,&quot; <i>Pediatr Infect Dis J</i>, 2011, 30(2):e29-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/21048525/pubmed\" target=\"_blank\" id=\"21048525\">21048525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaplan YC, Koren G. Use of ciprofloxacin during breastfeeding. <i>Can Fam Physician</i>. 2015;61(4):343-344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/26052598/pubmed\" target=\"_blank\" id=\"26052598\">26052598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krcm&eacute;ry V Jr, Filka J, Uher J, et al, &quot;Ciprofloxacin in Treatment of Nosocomial Meningitis in Neonates and in Infants: Report of 12 Cases and Review,&quot; <i>Diagn Microbiol Infect Dis</i>, 1999, 35(1):75-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/10529884/pubmed\" target=\"_blank\" id=\"10529884\">10529884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludlam H, Wreghitt TG, Thornton S, et al, &quot;Q Fever in Pregnancy,&quot; <i>J Infect</i>, 34(1):75-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/9120330/pubmed\" target=\"_blank\" id=\"9120330\">9120330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014 Feb;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/24457117 /pubmed\" target=\"_blank\" id=\"24457117 \">24457117 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. <i>Antimicrob Agents Chemother</i>. 2014;58(8):4392-4398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/24841264 /pubmed\" target=\"_blank\" id=\"24841264 \">24841264 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubio TT, Miles MV, Lettieri JT, et al, &quot;Pharmacokinetic Disposition of Sequential Intravenous/Oral Ciprofloxacin in Pediatric Cystic Fibrosis Patients With Acute Pulmonary Exacerbation,&quot; <i>Pediatr Infect Dis J</i>, 1997, 16(1):112-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/9002120/pubmed\" target=\"_blank\" id=\"9002120\">9002120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaad UB, abdus Salam M, Aujard Y, et al, &quot;Use of Fluoroquinolones in Pediatrics: Consensus Report of an International Society of Chemotherapy Commission,&quot; <i>Pediatr Infect Dis J</i>, 1995, 14(1):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/7715981/pubmed\" target=\"_blank\" id=\"7715981\">7715981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(2):133-164.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stockmann C, Sherwin CM, Zobell JT, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. <i>Pediatr Pulmonol</i>. 2013;48(3):211-220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/22949224 /pubmed\" target=\"_blank\" id=\"22949224 \">22949224 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis</i>. 2005;41(8):1159-1166.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/16163635 /pubmed\" target=\"_blank\" id=\"16163635 \">16163635 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Oever HL, Versteegh FG, Thewessen EA, et al, &quot;Ciprofloxacin in Preterm Neonates: Case Report and Review of the Literature,&quot; <i>Eur J Pediatr</i>, 1998, 157(10):843-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/9809826/pubmed\" target=\"_blank\" id=\"9809826\">9809826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al &quot;Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update,&quot; <i>Perit Dial Int</i>, 2012, 32(Suppl 2):S32-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-systemic-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Acute diarrhea in adults and children: a global perpective. 2012. Available at http://www.worldgastroenterology.org/guidelines/global-guidelines/acute-diarrhea/acute-diarrhea-english </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005. Available at http://www.who.int/maternal_child_adolescent/documents/9241592330/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). WHO guidelines on tularaemia. 2007. Available at <a href=\"http://www.cdc.gov/tularemia/resources/whotularemiamanual.pdf%20\" target=\"_blank\">http://www.cdc.gov/tularemia/resources/whotularemiamanual.pdf </a></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15951 Version 253.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9611220\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9611233\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9611234\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10586604\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442266\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10586944\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9611523\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9611236\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9611231\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10586949\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9611353\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10586605\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3198418\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9611306\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9611301\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9611302\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25855423\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9611328\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9611329\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F9611333\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9611259\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9611260\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10587004\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F10587005\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9611370\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9611373\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10806353\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9611525\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961927\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15951|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ciprofloxacin-systemic-drug-information\" class=\"drug drug_general\">Ciprofloxacin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=ciprofloxacin-systemic-patient-drug-information\" class=\"drug drug_patient\">Ciprofloxacin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}